Autor: "Fougerou-Leurent C" - OpacWWW

Skocz do pozycji: 1.

Tytuł:: Efficacy, safety and patient-reported outcomes of ledipasvir/sofosbuvir in NS3/4A protease inhibitor-experienced individuals with hepatitis C virus genotype 1 and HIV coinfection with and without cirrhosis (ANRS HC31 SOFTRIH study).
Autorzy:: Rosenthal E; Internal Medicine Department, CHU de Nice, Hôpital Archet 1, Nice, France.
Fougerou-Leurent C; Pharmacology Department, CHU Rennes, Rennes, France.; Inserm, CIC1414, Rennes, France.
Renault A; Inserm, CIC1414, Rennes, France.; Pharmacology Laboratory, Faculté de Médecine, Univ Rennes 1, Rennes, France.
Carrieri MP; Sciences Economiques & Sociales de la Santé & Traitement de l'Information Médicale, Inserm, IRD, Aix Marseille Univ, Marseille, France.; Observatoire Régional de la Santé Provence-Alpes-Côte d'Azur, Marseille, France.
Marcellin F; Sciences Economiques & Sociales de la Santé & Traitement de l'Information Médicale, Inserm, IRD, Aix Marseille Univ, Marseille, France.; Observatoire Régional de la Santé Provence-Alpes-Côte d'Azur, Marseille, France.
Garraffo R; Clinical Pharmacology and Toxicology Department, CHU de Nice, Nice, France.
Teicher E; Infectious Diseases Department, APHP, Hôpital Bicêtre, Le Kremlin Bicêtre, France.
Aumaitre H; Infectious and Tropical Diseases Department, Hôpital de Perpignan, Perpignan, France.
Lacombe K; Infectious Diseases Department, APHP, Hôpital Saint Antoine, Paris, France.
Bailly F; Hepatology Department, HCL, Hôpital de la Croix-Rousse, Lyon, France.
Billaud E; Infectious Diseases Department, CHU Nantes, Nantes, France.
Chevaliez S; Virology Department, APHP, Hôpital Henri Mondor, Créteil, France.
Dominguez S; Clinical Immunology Department, APHP, Hôpital Henri Mondor, Créteil, France.
Valantin MA; Infectious Diseases Department, APHP, Hôpital La Pitié Salpêtrière, Paris, France.
Reynes J; Infectious Diseases Department, CHU Montpellier, Montpellier, France.
Naqvi A; Infectious Diseases Department, CHU de Nice, Hôpital Archet 1, Nice, France.
Cotte L; Infectious Diseases Department, HCL, Hôpital de la Croix-Rousse, Lyon, France.
Metivier S; Hepatogastroenterology Department, CHU Toulouse, Toulouse, France.
Leroy V; Hepatogastroenterology Department, CHU Grenoble, Grenoble, France.
Dupon M; Infectious Diseases Department, CHU Bordeaux, Bordeaux, France.
Allegre T; Hemato Oncology Department, CH du Pays d'Aix, Aix-en-Provence, France.
De Truchis P; Infectious Diseases Department, APHP, Hôpital R Poincaré, Garches, France.
Jeantils V; Infectious Diseases Department, APHP, Hôpital J Verdier, Bondy, France.
Chas J; Infectious and Tropical Diseases Department, APHP, Hôpital Tenon, Paris, France.
Salmon-Ceron D; Infectious Diseases Department, APHP, Hôpital Cochin, Paris, France.
Morlat P; Internal Medicine and Infectious Diseases Department, CHU Bordeaux, Bordeaux, France.
Neau D; Infectious and Tropical Diseases Department, CHU Bordeaux, Bordeaux, France.
Perré P; Internal Medicine Department, CHD Vendée, La Roche sur Yon, France.
Piroth L; Infectious Diseases Department, CHU Dijon, Dijon, France.
Pol S; Hepato-Gastroenterology Department, APHP, Hôpital Cochin, Paris, France.
Bourlière M; Hepatogastroenterology Department, Hôpital Saint Joseph, Marseille, France.
Pageaux GP; Hepatogastroenterology Department, CHU Montpellier, Montpellier, France.
Alric L; Internal Medicine Department, CHU Toulouse, Toulouse, France.
Zucman D; Internal Medicine Department, Hôpital Foch, Suresne, France.
Girard PM; Infectious Diseases Department, APHP, Hôpital Saint Antoine, Paris, France.
Poizot-Martin I; Immuno and Clinical Hematology department, APHM Sainte-Marguerite, Aix Marseille Univ, Marseille, France.; Inserm U912 (SESSTIM), Marseille, France.
Yazdanpanah Y; Infectious and Tropical Diseases Department, APHP, Hôpital Bichat, Paris, France.
Raffi F; Infectious Diseases Department, CHU Nantes, Nantes, France.
Pabic EL; Pharmacology Department, CHU Rennes, Rennes, France.; Inserm, CIC1414, Rennes, France.
Tual C; Pharmacology Department, CHU Rennes, Rennes, France.; Inserm, CIC1414, Rennes, France.
Pailhé A; Unité de Recherche Clinique et Fondamentale sur les Hépatites Virales, ANRS (France Recherche Nord & Sud Sida-hiv Hépatites), Paris, France.
Amri I; Unité de Recherche Clinique et Fondamentale sur les Hépatites Virales, ANRS (France Recherche Nord & Sud Sida-hiv Hépatites), Paris, France.
Bellissant E; Pharmacology Department, CHU Rennes, Rennes, France.; Inserm, CIC1414, Rennes, France.; Pharmacology Laboratory, Faculté de Médecine, Univ Rennes 1, Rennes, France.
Molina JM; Hepatogastroenterology Department, APHP, Hôpital Saint Louis, Paris, France.; Pokaż więcej
Corporate Authors:: ANRS HC31 SOFTRIH Study Group
Źródło:: HIV medicine [HIV Med] 2018 Mar; Vol. 19 (3), pp. 227-237. Date of Electronic Publication: 2017 Dec 07.
Typ publikacji:: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms:: Patient Reported Outcome Measures*
Benzimidazoles/*administration & dosage
Coinfection/*drug therapy
Fluorenes/*administration & dosage
HIV Infections/*drug therapy
Hepatitis C, Chronic/*drug therapy
Sofosbuvir/*administration & dosage
Aged ; Benzimidazoles/adverse effects ; Drug Administration Schedule ; Female ; Fibrosis ; Fluorenes/adverse effects ; Genotype ; HIV Protease Inhibitors/therapeutic use ; HIV-1/genetics ; Hepacivirus/genetics ; Hepatitis C, Chronic/pathology ; Humans ; Male ; Middle Aged ; Pilot Projects ; Sofosbuvir/adverse effects ; Sustained Virologic Response ; Treatment Outcome

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Informacja

Wyszukujesz frazę ""Fougerou-Leurent C"" wg kryterium: Autor

Źródło danych

Ogranicz do:

Ogranicz do bazy

Typ dokumentu

Temat

Wydawca

Język